Intra-Cellular Therapies (ITCI) PT Raised to $38 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
BTIG raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $38.00 (from $36.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Establishment Labs Inc. (ESTA) PT Lowered to $93 at BTIG
- Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
- Insmed (INSM) PT Lowered to $195 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
The Children's Investment Fund (TCI), BTIGSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
